Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1996 Dec;49(12):994–997. doi: 10.1136/jcp.49.12.994

Assessment of commercial enzyme immunoassay for hepatitis C virus serotyping.

L M Webber 1, S Els 1, M B Taylor 1, W O Grabow 1
PMCID: PMC499648  PMID: 9038737

Abstract

AIMS: To assess a commercial enzyme immunoassay (EIA) for the serotyping of hepatitis C virus (HCV) for routine use in a diagnostic laboratory setting, as well as for noting the serotype prevalence of selected specimens. METHODS: Seventy six serum specimens, submitted to the laboratory for routine hepatitis studies between May 1992 and February 1996 and stored at -20 degrees C, were evaluated. These specimens were categorised into specific hepatic, renal, and paediatric clinical conditions. The specimens all tested positive for HCV antibodies on a screening EIA, with confirmation on a recombinant immunoblot assay (RIBA). Certain specimens were also HCV RNA positive by the reverse transcription polymerase chain reaction (RT-PCR). All the specimens were serotyped using the newly developed serotyping EIA. RESULTS: Twenty seven (35.5%) specimens were typable. Type 5 predominated (56%), followed by type 1 (33%), types 1 and 6 (7%) and type 3 (4%). The serotype 5 specimens showed 85% and 90% reactivity with recombinant antigens c100-3 and c22-3c, respectively; serotype 1 specimens showed 75% and 100% reactivity with these antigens. All serotype 5 specimens reacted with the c33-c antigen, but only 60% of serotype 1 specimens reacted with this antigen. The differences in the reactivity of the serotype 5 and serotype 1 specimens for c33-c antigen in the RIBA were significant, but no significant differences in reactivity for antigens c-1-1, c100-3, and c22-3 were noted. Serotype 3 specimens showed equal reactivity with all four antigens used in the RIBA. CONCLUSION: The serotyping EIA was easy to use, rapid, and cost effective compared with molecular assays. This assay seems to be ideal for the routine diagnostic laboratory setting, but could not be used for certain clinical specimens. The demonstration of serotypes 5, 1, and 3 was not unexpected in this cohort. The occurrence of serotype 6, although concurrent and more likely to be a false cross reaction with serotype 1 peptides, requires confirmation by molecular genotyping before it can be claimed that this type is present in South Africa.

Full text

PDF
994

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cerino A., Cividini A., Asti M., Lanza A., Silini E., Mondelli M. U. Comparative evaluation of two serologic typing methods for hepatitis C virus. J Clin Microbiol. 1996 Mar;34(3):714–716. doi: 10.1128/jcm.34.3.714-716.1996. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Davidson F., Simmonds P., Ferguson J. C., Jarvis L. M., Dow B. C., Follett E. A., Seed C. R., Krusius T., Lin C., Medgyesi G. A. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5' non-coding region. J Gen Virol. 1995 May;76(Pt 5):1197–1204. doi: 10.1099/0022-1317-76-5-1197. [DOI] [PubMed] [Google Scholar]
  3. Dhaliwal S. K., Prescott L. E., Dow B. C., Davidson F., Brown H., Yap P. L., Follett E. A., Simmonds P. Influence of viraemia and genotype upon serological reactivity in screening assays for antibody to hepatitis C virus. J Med Virol. 1996 Feb;48(2):184–190. doi: 10.1002/(SICI)1096-9071(199602)48:2<184::AID-JMV11>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  4. Dusheiko G. M., Khakoo S., Soni P., Grellier L. A rational approach to the management of hepatitis C infection. BMJ. 1996 Feb 10;312(7027):357–364. doi: 10.1136/bmj.312.7027.357. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Genetic diversity of hepatitis C virus: implications for pathogenesis, treatment, and prevention. Report of a meeting of Physicians and Scientists. Lancet. 1995 Mar 4;345(8949):562–566. [PubMed] [Google Scholar]
  6. Martin P. Hepatitis C genotypes: the key to pathogenicity? Ann Intern Med. 1995 Feb 1;122(3):227–228. doi: 10.7326/0003-4819-122-3-199502010-00012. [DOI] [PubMed] [Google Scholar]
  7. McOmish F., Yap P. L., Dow B. C., Follett E. A., Seed C., Keller A. J., Cobain T. J., Krusius T., Kolho E., Naukkarinen R. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. J Clin Microbiol. 1994 Apr;32(4):884–892. doi: 10.1128/jcm.32.4.884-892.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Nousbaum J. B., Pol S., Nalpas B., Landais P., Berthelot P., Bréchot C. Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group. Ann Intern Med. 1995 Feb 1;122(3):161–168. doi: 10.7326/0003-4819-122-3-199502010-00001. [DOI] [PubMed] [Google Scholar]
  9. Ohno T., Mizokami M., Tibbs C. J., Ohba K., Suzuki K., Wu R. R., Nouri-Aria K. T., Williams R. New genotype of hepatitis C virus in South Africa. J Med Virol. 1994 Apr;42(4):409–413. doi: 10.1002/jmv.1890420414. [DOI] [PubMed] [Google Scholar]
  10. Okamoto H., Mishiro S. Genetic heterogeneity of hepatitis C virus. Intervirology. 1994;37(2):68–76. doi: 10.1159/000150360. [DOI] [PubMed] [Google Scholar]
  11. Panigrahi A. K., Roca J., Acharya S. K., Jameel S., Panda S. K. Genotype determination of hepatitis C virus from northern India: identification of a new subtype. J Med Virol. 1996 Feb;48(2):191–198. doi: 10.1002/(SICI)1096-9071(199602)48:2<191::AID-JMV12>3.0.CO;2-I. [DOI] [PubMed] [Google Scholar]
  12. Pawlotsky J. M., Roudot-Thoraval F., Pellet C., Aumont P., Darthuy F., Remire J., Duval J., Dhumeaux D. Influence of hepatitis C virus (HCV) genotypes on HCV recombinant immunoblot assay patterns. J Clin Microbiol. 1995 May;33(5):1357–1359. doi: 10.1128/jcm.33.5.1357-1359.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Pawlotsky J. M., Roudot-Thoraval F., Simmonds P., Mellor J., Ben Yahia M. B., André C., Voisin M. C., Intrator L., Zafrani E. S., Duval J. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med. 1995 Feb 1;122(3):169–173. doi: 10.7326/0003-4819-122-3-199502010-00002. [DOI] [PubMed] [Google Scholar]
  14. Shindo M., Arai K., Sokawa Y., Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-alpha therapy. Ann Intern Med. 1995 Apr 15;122(8):586–591. doi: 10.7326/0003-4819-122-8-199504150-00005. [DOI] [PubMed] [Google Scholar]
  15. Smuts H. E., Kannemeyer J. Genotyping of hepatitis C virus in South Africa. J Clin Microbiol. 1995 Jun;33(6):1679–1681. doi: 10.1128/jcm.33.6.1679-1681.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Tisminetzky S., Gerotto M., Pontisso P., Chemello L., Prescott L. E., Rose K. A., Baralle F., Simmonds P., Alberti A. Comparison of genotyping and serotyping methods for the identification of hepatitis C virus types. J Virol Methods. 1995 Nov;55(3):303–307. doi: 10.1016/0166-0934(95)00067-x. [DOI] [PubMed] [Google Scholar]
  17. Tokita H., Okamoto H., Iizuka H., Kishimoto J., Tsuda F., Lesmana L. A., Miyakawa Y., Mayumi M. Hepatitis C virus variants from Jakarta, Indonesia classifiable into novel genotypes in the second (2e and 2f), tenth (10a) and eleventh (11a) genetic groups. J Gen Virol. 1996 Feb;77(Pt 2):293–301. doi: 10.1099/0022-1317-77-2-293. [DOI] [PubMed] [Google Scholar]
  18. Zignego A. L., Ferri C., Giannini C., Monti M., La Civita L., Careccia G., Longombardo G., Lombardini F., Bombardieri S., Gentilini P. Hepatitis C virus genotype analysis in patients with type II mixed cryoglobulinemia. Ann Intern Med. 1996 Jan 1;124(1 Pt 1):31–34. doi: 10.7326/0003-4819-124-1_Part_1-199601010-00006. [DOI] [PubMed] [Google Scholar]
  19. van der Poel C. L., Cuypers H. T., Reesink H. W. Hepatitis C virus six years on. Lancet. 1994 Nov 26;344(8935):1475–1479. doi: 10.1016/s0140-6736(94)90293-3. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES